Black Diamond Therapeutics, Inc. (BDTX) Stock
Healthcare · Biotechnology · Member of Other US Stocks
Black Diamond Therapeutics, Inc. (BDTX) closed at USD 1.70 on 2026-10-14, a change of -56.3 % over the past year, with a market capitalization of USD 99.97M.
Black Diamond Therapeutics, Inc. recent closing prices
| Date | Close (USD) |
|---|---|
| 2026-10-14 | 1.70 |
| 2026-10-13 | 1.68 |
| 2026-10-12 | 1.77 |
| 2026-10-09 | 1.83 |
| 2026-10-08 | 1.81 |
| 2026-10-07 | 1.83 |
| 2026-10-06 | 1.80 |
The most recent trading day is not shown. For full charts and indicators use the analysis page.
Black Diamond Therapeutics, Inc. key figures
- Previous close
- USD 1.70 (2026-10-14)
- 1-year change
- -56.3 %
- Market cap
- USD 99.97M
- Enterprise value
- USD 6.43M
- P/E ratio (trailing)
- -2.23
- P/E ratio (forward)
- -1.74
- EPS (trailing)
- -0.78
- EPS (forward)
- -1.00
- PEG ratio
- n/a
- Price to book
- 1.04
- Revenue growth
- n/a
- Earnings growth
- n/a
- Dividend per share (trailing)
- 0.00
- Short ratio
- 8.17
- Employees
- 21
- Analyst consensus (third-party)
- strong_buy
Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.
About Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Technical indicators and comparison
Show RSI, MACD, EMA, CCI and ADX for Black Diamond Therapeutics, Inc. and compare it with other stocks.
Analyze BDTXAll Other US Stocks stocksStock-scoring.com provides this page for information only. It is not investment advice or a recommendation to buy or sell Black Diamond Therapeutics, Inc. shares.